You're welcome- Here's a little more clarity from a relevant excerpt from the more recent May Earnings Transcript:
Aurinia Pharmaceuticals (AUPH) 10 May 22, 2022 Q1 Earnings call transcript
Unidentified Analyst
Hi, all this is Bill on for Joe, and thank you for taking your questions today. Congrats on the recent progress.
So one for us, can you just remind us on the on-going litigation with Sun pharmaceuticals? And has the company filed its response to the IPR? And when should we expect an update here and kind of how does this process unfold? Thank you.
Peter Greenleaf
Okay, thanks. And that was Joe Schwartz team over at SVB Leerink, sorry a little choppy coming in.
So let me repeat the question for everybody on the call. It related to on any updates on the Sun pharmaceutical litigation, the IPR process, and have we actually submitted our response to the IPR submitted by Sun to the U.S. Patent and Trade Office.
So to start with the Sun Pharma litigation, there's really no news there. The most recent update we'll have for us probably sometime in 2023 is that that litigation is on-going. We're calling that that is the litigation where we are suing Sun for patent infringement on our ophthalmic solution that we believe their product CEQUA infringes upon our patents for voclosporin's ophthalmic solution.
So no new news there, Joe, and wouldn't look for any until 2023.
On the IPR process, so officially, the patent office recognize the application, the date for response, so our response back to them is in late June. And then the PTAC [Ph] has, I believe, three months to review the initial filing alongside of our response.
So I would look for something in the in the back half of the year, call it late 3Q, early 4Q but nothing new.
We have not submitted our response as of yet because we're still formulating it. And we have until the latter part of June to get that submission in.
Unidentified Analyst
Great, thank you.
Operator
Thank you, Mr. Schwartz.
